Atrium Therapeutics, Inc. (RNA) Market Cap & Valuation Ratios
Atrium Therapeutics, Inc. (RNA) has a market cap of $140.3M and a price-to-sales ratio of 46.7, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · read by EquiReason
RNAAtrium Therapeutics, Inc.Follow RNA — free
—
Price chart with a free account
- Market cap
- 140.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| RNA | 0.1 | — | — | — | — | — | — | — |
| TRDA | 0.2 | — | 15.5 | — | — | -94% | — | -80% |
| SION | 0.2 | — | — | — | — | — | — | -44% |
| CHRS | 0.2 | — | 1.7 | — | — | +61% | -312% | — |
| MDWD | 0.2 | — | 12.6 | — | — | -40% | -268% | -126% |
| UPB | 0.2 | — | — | — | — | +16% | — | -61% |
| CDXS | 0.1 | — | 1.6 | — | -8.7% | +36% | -36% | -48% |
| CMPX | 0.1 | — | — | — | — | — | — | -81% |
| NKTX | 0.1 | — | — | — | — | — | — | -50% |
| AVXL | 0.1 | — | — | — | — | — | — | — |
| HUMA | 0.1 | — | 36.5 | — | — | +159% | — | — |
| Median of these 10 | — | 12.6 | — | -8.7% | +26% | -268% | -61% |
.
Growth vs. price
each dot a company · hover or tap for valuesAtrium Therapeutics, Inc. — questions
- What is Atrium Therapeutics, Inc.'s market cap?
- $140.3M.
- What is Atrium Therapeutics, Inc.'s price-to-sales ratio?
- 46.7.
Every figure on this page comes from Atrium Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.